Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) is a clinical-stage biotechnology company pioneering small molecule therapies for hematologic disorders, cancer, and immune diseases. This news hub provides investors and healthcare professionals with rigorously verified updates on RIGL's clinical developments, regulatory milestones, and strategic partnerships.
Key resources include earnings announcements, trial result disclosures, FDA submissions, and licensing agreements. Our curated collection enables stakeholders to track the progress of oral kinase inhibitors and novel therapeutic candidates through development pipelines.
Bookmark this page for centralized access to Rigel's latest scientific advancements and business updates. All content is maintained to reflect current developments while preserving historical context for longitudinal analysis of the company's progress.
Rigel Pharmaceuticals (Nasdaq: RIGL) has announced the granting of inducement awards under its Inducement Plan, as approved by the company's Compensation Committee. The grants, made in accordance with NASDAQ Listing Rule 5635(c)(4), consist of 23,350 stock options and restricted stock units awarded to seven non-executive employees.
These equity awards will vest over a four-year period with a one-year cliff vesting schedule. The grants serve as inducement material for employees entering into employment with Rigel, a biotechnology company founded in 1996 that focuses on developing therapies for hematologic disorders and cancer.
Rigel Pharmaceuticals (Nasdaq: RIGL) has reached a settlement agreement with Annora Pharma and Hetero Labs regarding patent litigation for its drug TAVALISSE® (fostamatinib disodium hexahydrate). The litigation arose from Annora's submission of an Abbreviated New Drug Application to the FDA for a generic version of TAVALISSE.
Under the settlement terms, Annora will receive a license to sell its generic product in Q2 2032 or earlier under certain circumstances. All ongoing litigation between the parties regarding TAVALISSE patents pending in New Jersey has been terminated. TAVALISSE is indicated for treating thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment.
Rigel Pharmaceuticals (NASDAQ: RIGL) has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich brings over 25 years of experience in developing cellular immunotherapies for cancer treatment, with expertise in clinical drug development and translational research.
Currently serving as CEO of Indapta Therapeutics, Dr. Frohlich previously led portfolio strategy at Juno Therapeutics and served as CMO at Dendreon , where he led the development and regulatory approval of PROVENGE®. His background includes positions at UCSF as an assistant adjunct professor of hematology/oncology, with degrees from Yale College and Harvard Medical School.
Dr. Frohlich will contribute to advancing Rigel's hematology and oncology pipeline, particularly focusing on the IRAK1/4 and IDH1 inhibitor programs for lower-risk myelodysplastic syndrome and glioma treatments respectively.
Rigel Pharmaceuticals (RIGL) reported strong financial results for Q4 and full year 2024. Q4 total revenue reached $57.6 million, including TAVALISSE sales of $31.0M, REZLIDHIA sales of $7.4M, and GAVRETO sales of $8.1M.
Full year 2024 revenue totaled $179.3 million, with TAVALISSE sales at $104.8M (12% growth), REZLIDHIA at $23.0M (118% growth), and GAVRETO at $17.1M. The company achieved its first full-year net income of $17.5 million, with cash reserves increasing by over $20M.
Notable developments include R289 receiving FDA Fast Track designation for treating previously-treated transfusion dependent lower-risk MDS and Orphan Drug designation for MDS treatment. For 2025, Rigel projects total revenue of $200-210 million, including net product sales of $185-192M and contract revenues of $15-18M, expecting continued profitability.
Rigel Pharmaceuticals (Nasdaq: RIGL) has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, March 4, 2025, after market close. The announcement will be followed by a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time), where senior management will discuss financial results and provide a business update.
Participants can join the conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The call and accompanying slides will also be webcast live from the Investor Relations section of Rigel's website and archived for 90 days afterward.
Rigel Pharmaceuticals is a biotechnology company founded in 1996 that focuses on discovering, developing, and providing novel therapies for patients with hematologic disorders and cancer. The company is headquartered in South San Francisco, California.
Rigel Pharmaceuticals (NASDAQ: RIGL) announced the enrollment of the first patient in a NIH/NHLBI-sponsored Phase 1 study evaluating fostamatinib in sickle cell disease (SCD) patients. The study will assess the safety and tolerability of escalating doses of fostamatinib, Rigel's oral SYK inhibitor, which is already approved as TAVALISSE® for chronic immune thrombocytopenia.
The open-label Phase 1 dose-escalation study aims to enroll approximately 20 patients with SCD. Patients will receive 100 mg twice daily for 14 days, potentially escalating to 150 mg twice daily for an additional 28 days if tolerated. The study will evaluate safety, tolerability, and investigate fostamatinib's mechanism of action in SCD, including its effects on red blood cell membrane integrity, sickling kinetics, and platelet activation.
The trial is being conducted at the NIH Clinical Center in Bethesda, Maryland, with study material provided by Rigel. SCD affects over 100,000 people in the United States and an estimated 7-8 million people worldwide.
Rigel Pharmaceuticals (RIGL) reported preliminary Q4 2024 total revenue of $57.6 million, including net product sales of TAVALISSE ($31.0M), REZLIDHIA ($7.4M), and GAVRETO ($8.1M). The company expects full-year 2024 total revenue of $179.3 million, with net product sales of $144.9 million.
Key developments include TAVALISSE surpassing $100 million in 2024 net product sales, R289 receiving FDA Orphan Drug designation for MDS treatment, and an exclusive license agreement with Dr. Reddy's for REZLIDHIA commercialization worth up to $40 million in total payments.
Looking ahead to 2025, Rigel anticipates total revenue of $200-210 million, including net product sales of $185-192 million and contract revenues of $15-18 million. The company expects to achieve positive net income while funding clinical development programs.
Rigel Pharmaceuticals (NASDAQ: RIGL) announced that its drug candidate R289 has received Orphan Drug designation from the FDA for treating myelodysplastic syndromes (MDS). R289, a dual inhibitor of IRAK1 and IRAK4, is currently in a Phase 1b study evaluating its safety, tolerability, and preliminary activity in patients with lower-risk MDS who haven't responded to previous treatments.
The Orphan Drug designation provides several benefits, including tax credits, FDA fee exemptions, and potential seven-year market exclusivity upon approval. R289 had previously received Fast Track designation for treating patients with previously-treated transfusion-dependent lower-risk MDS.
R289 is a prodrug of R835 that works by blocking inflammatory cytokine production in response to toll-like receptor and interleukin-1 receptor family signaling, which are thought to cause pro-inflammatory conditions in the bone marrow of lower-risk MDS patients.
Rigel Pharmaceuticals (Nasdaq: RIGL), a commercial stage biotechnology company specializing in hematologic disorders and cancer treatments, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's president and CEO, Raul Rodriguez, will deliver a company overview on Thursday, January 16, 2025, at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco.
The presentation will be accessible via live webcast through the Investor Relations section of Rigel's website. Founded in 1996 and headquartered in South San Francisco, California, Rigel focuses on discovering, developing, and providing innovative therapies for patients with hematologic disorders and cancer.
Rigel Pharmaceuticals (Nasdaq: RIGL) has announced the granting of inducement awards under its Inducement Plan, as approved by the company's Compensation Committee. The grants, made in accordance with NASDAQ Listing Rule 5635(c)(4), consist of 46,131 stock options awarded to eight non-executive employees. These options will vest over a four-year period with a one-year cliff.
The awards were granted as material inducements for these employees entering into employment with Rigel. The company, founded in 1996 and based in South San Francisco, California, focuses on developing and providing novel therapies for patients with hematologic disorders and cancer.
